Health
Autism drug L1-79 advances to Phase 3 FDA clinical trials
Yamo Pharmaceuticals is moving its experimental autism drug L1-79 into Phase 3 trials in early 2027 after drawing 6,000 inquiries from 90 countries.
Bringing you stories that vibe with your fashion